留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《2022 NCCN胃癌临床实践指南》更新解读

刘媛 赵林

刘媛, 赵林. 《2022 NCCN胃癌临床实践指南》更新解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0271
引用本文: 刘媛, 赵林. 《2022 NCCN胃癌临床实践指南》更新解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0271
LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0271
Citation: LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0271

《2022 NCCN胃癌临床实践指南》更新解读

doi: 10.12290/xhyxzz.2022-0271
详细信息
    通讯作者:

    赵林,E-mail:wz20010727@aliyun.com

  • 中图分类号: R735.2;R730.5

Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer

  • 摘要: 近日,美国国立综合癌症网发布了2022年最新版胃癌临床实践指南。该版指南不仅细化了对腹腔转移性疾病的评估、术后放疗的适应症以及三药联合化疗的推荐,更为重要的是首次推荐高通量测序技术用于MSI/MMR状态的检测,并推荐将MSI/MMR状态的检测扩大至全人群。同时,在后线治疗中新增了数种基于分子分型的新药推荐,指明了未来胃癌精准治疗的方向。本文将对新版胃癌临床实践指南,特别是其更新部分进行解读,以期为临床实践提供指导和帮助。
  • [1] Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20:167-192.
    [2] International Agency for Research on Cancer.GLOBOCAN 2020:stomach cancer fact sheet[EB/OL](. 2020-12)[2021-07-09].https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomachfact-sheet.pdf.
    [3] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021, 71:209-249.
    [4] Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer:epidemiology, prevention, classification, and treatment[J]. Cancer Manag Res, 2018, 10:239-248.
    [5] Ma J, Shen H, Kapesa L, et al. Lauren classification and individualized chemotherapy in gastric cancer[J]. Oncol Lett, 2016, 11:2959-2964.
    [6] Hu B, El Hajj N, Sittler S, et al. Gastric cancer:classification, histology and application of molecular pathology[J]. J Gastrointest Oncol, 2012, 3:251-261.
    [7] Crew KD, Neugut AI. Epidemiology of gastric cancer[J]. World J Gastroenterol, 2006, 12:354-362.
    [8] Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]8th ed. New York, Springer, 2017.
    [9] Sarela AI, Lefkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging[J]. Am J Surg, 2006, 191:134-138.
    [10] Abdalla EK, Pisters PWT. Staging and preoperative evaluation of upper gastrointestinal malignancies[J]. Semin Oncol, 2004, 31:513-529.
    [11] Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer:natural history and outcome of 291 patients[J]. Ann Surg Oncol, 2010, 17:3173-3180.
    [12] Thierry Andre. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA):The GERCOR NEONIPIGA phase II study. 2022 ASCO GI Poster 244
    [13] Song Li. Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer:A meta-analysis and systemic review. 2022 ASCO GI Poster 291
    [14] Trabucco SE, Gowen K, Maund SL, et al. A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67, 000 Patient Samples[J]. J Mol Diagn, 2019, 21:1053-1066.
    [15] Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel[J]. Clin Cancer Res, 2019, 25:7035-7045.
    [16] Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma[J].Clin Cancer Res, 2018, 24:6248-6256.
    [17] Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastic cancer[J]. J Clin Oncol, 2010, 28:2430-2436.
    [18] Park SH, Sohn TS, Lee J, et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrence chemoradiotherapy in gastric cancer:final report of the Adjuvant Chemoradiotherapy In Stomach Tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33:3130-3136.
    [19] Lee J, Lim do H, Kim S, et a. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial[J]. J Clin Oncol, 2012, 30:268-273.
    [20] Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant singleagent S1, S-1 with oxaliplatin, and postoperative chemoradiotion with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection:the ARTIST 2 trial[J]. Ann Oncol, 2021, 32:368-374.
    [21] Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer:a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)[J]. Eur J Cancer, 2013, 49:835-842.
    [22] Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group[J]. J Clin Oncol, 2006, 24:4991-4997.
    [23] Elsaid AA, Elkerm Y. Final results of a randomized phase Ⅲ trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer[J]. J Clin Oncol, 2005, 23:4014.
    [24] Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer:a randomized phase Ⅱ study[J]. Ann Oncol, 2015, 26:149-156.
    [25] Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma:a study of the US Gastric Cancer Consortium[J]. J Clin Oncol 2015, 33:3874-3879.
    [26] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3, open-label, randomised controlled trial[J].Lancet, 2010, 376:687-697.
    [27] Chung HC, Bang YJ, Fuchs CS, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer:KEYNOTE-811[J].Future Oncol, 2021, 17:491-501.
    [28] Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649):a randomised, open-label, phase 3 trial[J].Lancet, 2021, 398:27-40.
    [29] Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD):an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383:31-39.
    [30] Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind, randomised phase 3 trial[J].Lancet Oncol, 2014, 15:1224-1235.
    [31] Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J]. N Engl J Med, 2020, 382:2419-2430.
    [32] Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors:a combined analysis of two cohorts in the GARNET study[J]. J Clin Oncol, 2021, 39:2564.
    [33] Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer:a nonrandomized phase 1 clinical trial[J]. JAMA Oncol, 2020, 6:1766-1772.
    [34] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357:409-413.
    [35] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372:2509-2520.
    [36] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:results from the phase II KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38:1-10.
  • 加载中
计量
  • 文章访问数:  10
  • HTML全文浏览量:  3
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-11
  • 录用日期:  2022-05-23
  • 网络出版日期:  2022-06-23

目录

    /

    返回文章
    返回